In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

por Laukkanen, S, Grönroos, T, Pölönen, P, Kuusanmäki, H, Mehtonen, J, Cloos, J, Ossenkoppele, G, Gjertsen, B, Øystein, B, Heckman, C, Heinäniemi, M, Kontro, M, Lohi, O
Publicado 2017

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

por Eldfors, S, Kuusanmäki, H, Kontro, M, Majumder, M M, Parsons, A, Edgren, H, Pemovska, T, Kallioniemi, O, Wennerberg, K, Gökbuget, N, Burmeister, T, Porkka, K, Heckman, C A
Publicado 2017

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

por Malani, D, Murumägi, A, Yadav, B, Kontro, M, Eldfors, S, Kumar, A, Karjalainen, R, Majumder, M M, Ojamies, P, Pemovska, T, Wennerberg, K, Heckman, C, Porkka, K, Wolf, M, Aittokallio, T, Kallioniemi, O
Publicado 2017

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

por Pietarinen, P O, Pemovska, T, Kontro, M, Yadav, B, Mpindi, J P, Andersson, E I, Majumder, M M, Kuusanmäki, H, Koskenvesa, P, Kallioniemi, O, Wennerberg, K, Heckman, C A, Mustjoki, S, Porkka, K
Publicado 2015